189 related articles for article (PubMed ID: 9001925)
1. Gemcitabine: safety profile unaffected by starting dose.
Martin C; Pollera CF
Int J Clin Pharmacol Res; 1996; 16(1):9-18. PubMed ID: 9001925
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of gemcitabine.
Tonato M; Mosconi AM; Martin C
Anticancer Drugs; 1995 Dec; 6 Suppl 6():27-32. PubMed ID: 8718422
[TBL] [Abstract][Full Text] [Related]
3. Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer.
Cortes-Funes H; Martin C; Abratt R; Lund B
Anticancer Drugs; 1997 Jul; 8(6):582-7. PubMed ID: 9300572
[TBL] [Abstract][Full Text] [Related]
4. Phase II studies of gemcitabine for non-small cell lung cancer in Japan.
Fukuoka M; Takada M; Yokoyama A; Kurita Y; Niitani H
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-42-S7-46. PubMed ID: 9194479
[TBL] [Abstract][Full Text] [Related]
5. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Anderson H; Lund B; Bach F; Thatcher N; Walling J; Hansen HH
J Clin Oncol; 1994 Sep; 12(9):1821-6. PubMed ID: 8083706
[TBL] [Abstract][Full Text] [Related]
6. Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.
Abratt RP; Hacking DJ; Goedhals L; Bezwoda WR
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-18-S8-23. PubMed ID: 9207311
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine--a safety review.
Aapro MS; Martin C; Hatty S
Anticancer Drugs; 1998 Mar; 9(3):191-201. PubMed ID: 9625429
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer.
Shepherd FA; Abratt RP; Anderson H; Gatzemeier U; Anglin G; Iglesias J
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-50-S7-55. PubMed ID: 9194481
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.
Fleming DR; Glisson SD; Bhupalam L; Michelson GD; Goldsmith GH; LaRocca RV
Am J Clin Oncol; 2000 Aug; 23(4):349-52. PubMed ID: 10955861
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms.
Levitt ML; Kassem B; Gooding WE; Miketic LM; Landreneau RJ; Ferson PF; Keenan R; Yousem SA; Lindberg CA; Trenn MR; Ponas RS; Tarasoff P; Sabatine JM; Friberg D; Whiteside TL
Lung Cancer; 2004 Mar; 43(3):335-44. PubMed ID: 15165093
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results of an ongoing phase I/II study.
Steward WP; Dunlop DJ; Cameron C; Talbot DC; Kleisbauer JP; Thomas P; Guerin JC; Perol M; Sanson C; Dabouis G
Anticancer Drugs; 1995 Dec; 6 Suppl 6():33-7. PubMed ID: 8718423
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule.
Martin C; Lund B; Anderson H; Thatcher N
Anticancer Drugs; 1996 May; 7(3):351-7. PubMed ID: 8792011
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
Ng EW; Sandler AB; Robinson L; Einhorn LH
Am J Clin Oncol; 1999 Dec; 22(6):550-3. PubMed ID: 10597737
[TBL] [Abstract][Full Text] [Related]
14. A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
Manegold C; Drings P; von Pawel J; Ricci S; Dornoff W; van Walree N; ten Bokkel Huinink W; Chemaissani A; Stahel P; Bergman B; Wagenius G; Sederholm C; Mattson K; Liippo K; Kellokumpu-Lehtinen P
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-13-S8-17. PubMed ID: 9207310
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: a review.
Hansen HH; Sørensen JB
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-38-S7-41. PubMed ID: 9194478
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.
Abratt RP; Bezwoda WR; Falkson G; Goedhals L; Hacking D; Rugg TA
J Clin Oncol; 1994 Aug; 12(8):1535-40. PubMed ID: 8040664
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.
Shepherd FA; Cormier Y; Burkes R; Evans WK; Goss G; Klimo P; Feld R; Taylor M
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-27-S8-30. PubMed ID: 9207313
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer.
Gatzemeier U; Manegold C; Eberhard W; Wilke HJ; Chomy F; Chomy P; Khayat D; Blatter J; Seeber S; Drings P
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-36-S8-38. PubMed ID: 9207315
[TBL] [Abstract][Full Text] [Related]
19. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
Fossella FV; Lippman SM; Shin DM; Tarassoff P; Calayag-Jung M; Perez-Soler R; Lee JS; Murphy WK; Glisson B; Rivera E; Hong WK
J Clin Oncol; 1997 Jan; 15(1):310-6. PubMed ID: 8996158
[TBL] [Abstract][Full Text] [Related]
20. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study.
Akrivakis K; Schmid P; Flath B; Schweigert M; Sezer O; Mergenthaler HG; Possinger K
Anticancer Drugs; 1999 Jul; 10(6):525-31. PubMed ID: 10885899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
